Loading clinical trials...
Loading clinical trials...
Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Agennix
NCT04955210 · Critical Illness, Severe Sepsis
NCT06143137 · Severe Sepsis
NCT05296590 · Bacteremia, Bacteremia Sepsis, and more
NCT02473263 · Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit
NCT02664753 · Severe Sepsis, Shock, Septic, and more
Loma Linda University Medical Center
Loma Linda, California
UC Davis Medical Center
Sacramento, California
Olive View- UCLA Medical Center
Sylmar, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions